Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04447417 · ClinicalTrials.gov registry record · Phase 4
Dupilumab Skin Barrier Function Study in Atopic Dermatitis
A Phase 4 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
NCT04447417 is a Phase 4 study that has completed, run by Sanofi. The registered enrollment target is 52 participants.
The verdict
NCT04447417, a Phase 4 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
Study Summary
Primary Objective: \- Evaluate changes in skin barrier function with transepidermal water loss (TEWL) assessed after skin tape stripping (STS) in pre-defined lesional skin in participants with moderate to severe atopic dermatitis (AD) treated with dupilumab. Secondary Objectives: * Evaluate changes in skin barrier function with TEWL assessed after STS in pre-defined lesional and non-lesional skin in participants with moderate to severe AD treated with dupilumab in reference to normal skin of healthy volunteers. * Evaluate time course of skin barrier function with TEWL assessed before and after STS in pre-defined lesional and non-lesional skin in participants with moderate to severe AD treated with dupilumab in reference to normal skin of healthy volunteers.
Interventions
- DRUG Dupilumab SAR231893
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2020-07-16 |
| Est. Completion | 2021-06-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04447417
The ClinicalTrials.gov registry entry for NCT04447417 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dupilumab SAR231893 is the first listed.
NCT04447417 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04447417 about?
NCT04447417 is a clinical study titled "Dupilumab Skin Barrier Function Study in Atopic Dermatitis". Primary Objective: \- Evaluate changes in skin barrier function with transepidermal water loss (TEWL) assessed after skin tape stripping (STS) in pre-defined lesional skin in participants with moderate to severe atopic dermatitis (AD) treated with dupilumab. Secondary Objectives: * Evaluate chang...
What is the current status of trial NCT04447417?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2020-07-16. Estimated completion is 2021-06-17.
What interventions are being tested in trial NCT04447417?
The interventions under investigation include: Dupilumab SAR231893 (DRUG).
Who is sponsoring clinical trial NCT04447417?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.